BONESUPPORT, the maker of an injectable bone substitute for orthopedic trauma and bone infections, has signed a multi-year distribution agreement with Biomet, Inc., a manufacturer of musculoskeletal medical products.
Biomet to Distribute CERAMENT Bone Filler
1 min read Premium comments
Secondary
Biomet will have exclusive distribution rights for BONESUPPORT’s proprietary CERAMENT Bone Void Filler product line in the United States and Canada for orthopedic, trauma and foot and ankle indications.
“The completion of this agreement with such a distinguished partner as Biomet is an endorsement of the CERAMENT product line, ” said Lloyd Diamond, CEO of BONESUPPORT. “In Biomet we have found an experienced partner dedicated to bringing innovative treatments to the world. Biomet’s leadership position and strong distribution channel provide full and immediate territory coverage for CERAMENT in two critical markets, the United States and Canada, and provides an excellent platform from which we can launch future product line extensions.”
Joel Higgins, vice president and general manager of Biomet Biologics, said that he was “very excited to be partnering with BONESUPPORT to bring the CERAMENT product line to the U.S. and Canadian markets.”
BONESUPPORT was founded in 1999 and is based in Lund, Sweden, with subsidiary locations in the U.S. and Germany. The company reports that scientific research of CERAMENT spans more than 11 years and over 45 pre-clinical, clinical and animal studies.
CERAMENT is a synthetic bioceramic bone substitute that is designed to mimic human cancellous bone. CERAMENT’s particular blend of calcium sulphate and hydroxyapatite combined with liquid iohexol creates a highly injectable, osteoconductive and bioactive material.
The cement particular formulation is designed to provide short-term resorbable support for the fracture or bone void providing rapid pain relief and stabilization. The compound will also provide longer-term osteoconductive support which enhances new bone growth. CERAMENT is a patented technology results in the unique qualities of this biomaterial.
Biomet is headquartered in Warsaw, Indiana, and its subsidiaries currently distribute products in approximately 90 countries.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.